The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers

Cancer Letters

Volumn 185, Issue 1, 2002, Pages 103-109

  Atema, Annemieke ^a   Chène, Patrick ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chemoresistance; Chemosensitivity; Gain of function; p53; Tetramerisation

Indexed keywords

BINDING PROTEIN; CISPLATIN; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; PROTEIN P53; TETRAMER; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CHLORAMPHENICOL ACETYLTRANSFERASE; PROTEIN;

ARTICLE; CANCER RESISTANCE; CARCINOMA; CELL LINE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; CELL CULTURE; CLONOGENIC ASSAY; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MUTATION; OSTEOSARCOMA; PHYSIOLOGY; PROTEIN BINDING; SERODIAGNOSIS; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BETA-GALACTOSIDASE; BLOTTING, WESTERN; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CISPLATIN; COLONY-FORMING UNITS ASSAY; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENES, P53; HUMAN; MUTATION; OSTEOSARCOMA; PRECIPITIN TESTS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN P53; PROTEINS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037044570     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00318-X     Document Type: Article

References (22)

1. P53 website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis
2. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerisation
3. Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA
4. Selective loss of endogenous p21waf1/cip1 induction underlies the G1 checkpoint defect of monomeric p53 proteins
5. The dihedral symmetry of the p53 tetramerisation domain mandates a conformational switch upon DNA binding
6. Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties
7. Oligomerisation is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells
8. Characterisation of p53 oligomerisation domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members
9. Characterisation of p53 mutants identified in human tumors with a missense mutation in the tetramerisation domain
10. Characterisation of the oligomerisation defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome
11. Function, oligomerisation, and conformation of tumor-associated p53 proteins with mutated C-terminus
12. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation
13. In vitro analysis of the dominant negative effect of p53 mutants
14. In vitro structure-function analysis of the beta-strand 326-333 of human p53
15. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain
16. P53 mutants without a functional tetramerisation domain are not oncogenic
17. A leucine-rich nuclear export signal in the p53 tetramerisation domain: Regulation of subcellular localisation and p53 activity by NES masking
18. Gain of function mutations in p53
19. Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point
20. Mutant p53 protein expression interferes with p53-independent apoptotic pathways
21. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy